This training course in conjunction with the COST Action CA16125 has led to the establishment of three new European wide cohorts of patients with chILD including those focused on (a) Neuroendocrine Cell Hyperplasia of Infancy (NEHI), (b) ABCA3 mutation related chILD and (c) diffuse alveolar haemorrhage (DAH). This evidence concerns the gene ABCA3 and interstitial lung disease specific to childhood.